CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ:AVEO) today reported its second quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.
“Our strategy for building value remains focused on our AV-380 program in cachexia and in leveraging partner resources to advance the development of our clinical pipeline,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “The partnership with Biodesix for the development and commercialization of ficlatuzumab, announced in the second quarter, is an important example of execution against this strategy. We have also demonstrated progress across the pipeline, presenting first-in-human data for AV-203 at ASCO, regaining worldwide rights to tivozanib and executing on our strategy of bringing AV-380 to the clinic.”
Help employers find you! Check out all the jobs and post your resume.
